Search results for "Pharmacological"

showing 10 items of 131 documents

Liver follicular helper T-cells predict the achievement of virological response following interferon-based treatment in HCV-infected patients.

2012

Background Here, we assessed the presence of intrahepatic follicular helper T-cells (TFH) in a cohort of consecutive genotype 1 (G1) chronic hepatitis C (CHC) patients comprising non-responders (NRs), relapsers (RRs) or those with sustained virological response (SVR) to pegylated interferon and ribavirin, and tested their relation with the response to antiviral treatment. Methods A total of 78 patients with G1 CHC (30 SVR, 15 RR and 33 NR), comparable for sex, age, viral load and fibrosis were evaluated by immunohistochemistry for liver content of PD1+Bcl6+ TFH cells. The number of TFH cells in the immunostained sections was counted out of five representative high-power microscopic fields (…

AdultMaleGenotypeHepacivirusSettore MED/08 - Anatomia PatologicaAntiviral AgentsPolymorphism Single NucleotideBiomarkers PharmacologicalPolyethylene GlycolsCohort StudiesPharmacotherapyInterferonRibavirinGenotypeFollicular phaseHumansMedicinePharmacology (medical)liver biopsy Interferon-alpha follicular helper T-cellsPharmacologySettore MED/12 - Gastroenterologiabusiness.industryInterleukinsInterferon-alphaT-Lymphocytes Helper-InducerHepatitis CHepatitis C ChronicMiddle AgedViral LoadPrognosismedicine.diseaseImmunohistochemistryRecombinant ProteinsCD4 Lymphocyte CountInfectious DiseasesLiverImmunologyCohortRNA ViralImmunohistochemistryDrug Therapy CombinationFemalehcv immunohistochemistryInterferonsbusinessCohort studymedicine.drug
researchProduct

Influence of CYP3A5 and ABCB1 gene polymorphisms and other factors on tacrolimus dosing in Caucasian liver and kidney transplant patients

2011

Tacrolimus is a substrate of cytochrome P4503A (CYP3A) enzymes as well as of the drug transporter ABCB1. We have investigated the possible influence of CYP3A5 and ABCB1 single nucleotide polymorphisms (SNPs) and other factors (e.g. albumin, hematocrit and steroids) on tacrolimus blood levels achieved in a population of Caucasian liver (n=51) and kidney (n=50) transplant recipients. At 1, 3 and 6 months after transplantation, tacrolimus doses (mg/kg/day) and trough blood levels (C0) were recorded and the weight-adjusted tacrolimus dosage (mg/kg/day) was calculated. Polymerase chain reaction followed by restriction fragment length polymorphism analysis was used for genotyping CYP3A5*1 and *3 …

AdultMalemedicine.medical_specialtyATP Binding Cassette Transporter Subfamily BGenotypemedicine.medical_treatmentDNA Mutational AnalysisPopulationSingle-nucleotide polymorphismLiver transplantationBiologyKidneyPolymorphism Single NucleotideGastroenterologyBiomarkers PharmacologicalTacrolimusWhite PeopleGene FrequencyInternal medicineGeneticsmedicineCytochrome P-450 CYP3AHumansDrug Dosage CalculationsATP Binding Cassette Transporter Subfamily B Member 1educationAllele frequencyAllelesKidney transplantationAgededucation.field_of_studyKidney metabolismGeneral MedicineMiddle Agedmedicine.diseaseKidney TransplantationTacrolimusLiver TransplantationTransplantationsurgical procedures operativeItalyLiverImmunologySettore BIO/14 - FarmacologiaPharmacogenetics CYP3A5 ABCB1 TacrolimusTransplant patientsFemaleImmunosuppressive AgentsPolymorphism Restriction Fragment LengthInternational Journal of Molecular Medicine
researchProduct

Pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance identifies very early cardiac involvement in systemic scler…

2017

Objective To evaluate occult cardiac involvement in asymptomatic systemic sclerosis (SSc) patients by pharmacological stress, rest perfusion and delayed enhancement cardiac magnetic resonance (CMR), for a very early identification of patients at higher risk of cardiac-related mortality. Methods Sixteen consecutive patients with definite SSc, fulfilling the American College of Rheumatology/European League Against Rheumatism 2013 classification criteria in less than 1 year from the onset of Raynaud's phenomenon, underwent pharmacological stress, rest perfusion and delayed enhancement CMR. At enrollment, no patient showed signs and/or symptoms suggestive for cardiac involvement. No patient sho…

AdultMalemedicine.medical_specialtyAdenosineHeart diseaseHeart DiseasesVasodilator AgentsContrast MediaMagnetic Resonance Imaging CineAsymptomaticCardiac magnetic resonance imaging with pharmacological stress; Myocardial perfusion defect; Systemic sclerosis; Systemic sclerosis heart involvement; Rheumatology030218 nuclear medicine & medical imaging03 medical and health sciencesMyocardial perfusion imagingCoronary circulation0302 clinical medicineRheumatologyPredictive Value of TestsInternal medicineCoronary CirculationCardiac magnetic resonance imaging with pharmacological stressMultidetector Computed TomographymedicineHumans030203 arthritis & rheumatologyScleroderma Systemicmedicine.diagnostic_testbusiness.industryMicrocirculationMyocardial Perfusion Imagingmedicine.diseaseRheumatologymyocardial perfusion defectSettore MED/16 - Reumatologiamedicine.anatomical_structureEarly DiagnosisVentriclecardiac magnetic resonance imaging with pharmacological streAsymptomatic Diseasessystemic sclerosis heart involvementSystemic sclerosisFemaleRadiologymedicine.symptombusinessPerfusionsystemic sclerosiRheumatism
researchProduct

Gabor frames for classification of paroxysmal and persistent atrial fibrillation episodes

2016

[EN] In this study, we propose a new classification method for early differentiation of paroxysmal and persistent atrial fibrillation episodes, i.e. those which spontaneously or with external intervention will return to sinus rhythm within 7 days of onset from the ones where the arrhythmia is sustained for more than 7 days. Today, clinicians provide patients classification once the course of the arrhythmia has been disclosed. This classification problem is dealt with in this study. We study a sparse representation of surface electrocardiogram signals by means of Gabor frames and afterwards we apply a linear discriminant analysis. Thus, we provide an early discrimination, obtaining promising…

AdultMalemedicine.medical_specialtyEXPRESION GRAFICA EN LA INGENIERIAmedicine.medical_treatment0206 medical engineeringBiomedical EngineeringBiophysicsCatheter ablation02 engineering and technology030204 cardiovascular system & hematologyPharmacological treatmentElectrocardiography03 medical and health sciences0302 clinical medicineInternal medicineHumansMedicineSinus rhythmAgedAged 80 and overbusiness.industrySignal Processing Computer-AssistedAtrial fibrillationMiddle Agedmedicine.diseaseLinear discriminant analysisAtrial fibrillation020601 biomedical engineeringElectrocardiogramPersistent atrial fibrillationCohortCatheter AblationCardiologyClassification methodsFemaleGabor framesbusinessMedical Engineering & Physics
researchProduct

Efficacy and pharmacological appropriateness of cinnarizine and dimenhydrinate in the treatment of vertigo and related symptoms

2021

Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical …

AdultMalepharmacological treatment of vertigomedicine.medical_specialtyCinnarizineHealth Toxicology and MutagenesisDiseasedimenhydrinateArticleCinnarizine Dimenhydrinate Dizziness Pharmacological treatment of vertigo Vertigo Adult Double-Blind Method Drug Combinations Female Histamine H1 Antagonists Humans Male Middle Aged Cinnarizine Dimenhydrinatevertigo03 medical and health sciences0302 clinical medicinePharmacotherapyDouble-Blind MethodVertigoInternal medicinemedicineotorhinolaryngologic diseasesHumans030212 general & internal medicinecinnarizine030223 otorhinolaryngologydizzinessBalance (ability)biologybusiness.industryPublic Health Environmental and Occupational HealthRMiddle Agedbiology.organism_classificationDimenhydrinateDrug CombinationsTolerabilityConcomitantHistamine H1 AntagonistsMedicineFemalebusinessmedicine.drug
researchProduct

2021 revised algorithm for the management of knee osteoarthritis-the Chinese viewpoint.

2021

Abstract Aim The European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide from 2014, but in 2019 an update was published. Based on this algorithm, a Working Group (WG), including ESCEO members and Chinese experts, wished to see how the new ESCEO algorithm was perceived by Chinese experts in knee OA and how it was integrated into their clinical practice. Methods A WG was held between members of the international ESCEO task force and a group of Chinese experts. Results Non-pharmacological approach should be combined with pharmacological interventions. …

AgingChinaSymptomatic slow-acting drugs for osteoarthritisOsteoarthritis03 medical and health sciences0302 clinical medicineMedicineHumans030212 general & internal medicineKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithm · ChinaConsensus Document030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryGeriatrics gerontologyTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis Kneemedicine.diseaseClinical PracticeAlgorithmPharmacological interventionsGeriatrics and GerontologybusinessAlgorithmAlgorithmsAging clinical and experimental research
researchProduct

2019 revised algorithm for the management of knee osteoarthritis: the Southeast Asian viewpoint

2021

Abstract Background Since 2014, the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO) algorithm for the management of knee osteoarthritis (OA) is available worldwide. Aim Based on this document, a Southeast Asia Working Group (SEAWG) wished to see how the new ESCEO algorithm developed in 2019 was perceived by Southeast Asian experts and how it was integrated into their clinical practice. Methods A SEAWG was set up between members of the international ESCEO task force and a group of Southeast Asian experts. Results Non-pharmacological management should always be combined with pharmacological management. In step 1, symptoma…

AgingSymptomatic slow-acting drugs for osteoarthritisPharmacological managementOsteoarthritisSoutheast asianSoutheast asia03 medical and health sciences0302 clinical medicineMedicine and Health SciencesHumansMedicine030212 general & internal medicineLimited evidenceConsensus DocumentReimbursement030203 arthritis & rheumatologyGlucosamineKnee osteoartrhitisbusiness.industryTask forceAnti-Inflammatory Agents Non-SteroidalChondroitin SulfatesPatented crystalline glucosamine sulfateOsteoarthritis KneeKnee osteoartrhitis · Patented crystalline glucosamine sulfate · Symptomatic slow-acting drugs for osteoarthritis · Algorithmmedicine.diseaseAlgorithmClinical PracticeGeriatrics and GerontologybusinessAlgorithmAlgorithms
researchProduct

Challenges in the pharmacological treatment of geriatric asthma

2016

ABSTRACTAsthma in older populations is characterized by frequent comorbid conditions, which increase the risk of side effects and of detrimental interactions between respiratory and non-respiratory drugs. These observations lead to the need to manage asthma in older populations by applying a multidimensional assessment and a multidisciplinary treatment; therefore, we favor the use of the ‘geriatric’ term to define asthma in the elderly. Geriatric asthma is a complex disease, which may not necessarily imply that it is also complicated, although the two conditions may often coexist. On this basis, the switch from an organ-driven management to the holistic approach may be the key factor to att…

Agingmedicine.medical_specialtyComplex diseaseComorbidityDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioAnti-asthmatic AgentPharmacological treatmentOlder population03 medical and health sciences0302 clinical medicineMultidisciplinary approachAnimalsHumansMedicinePharmacology (medical)Anti-Asthmatic Agents030212 general & internal medicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicinePsychiatryAgedAsthmabusiness.industryAge FactorsGeneral Medicinemedicine.diseaseComorbidityAsthmaInhaled treatment030228 respiratory systemAdherencePharmacology Toxicology and Pharmaceutics (all)businessExpert Review of Clinical Pharmacology
researchProduct

Choosing wisely: Practical considerations on treatment efficacy and safety of asthma in the elderly

2015

The prevalence of asthma in the most advanced ages is similar to that of younger ages. However, the concept that older individuals may suffer from allergic asthma has been largely denied in the past, and a common belief attributes to asthma the definition of "rare" disease. Indeed, asthma in the elderly is often underdiagnosed or diagnosed as COPD, thus leading to undertreatment of improper treatment. This is also due to the heterogeneity of clinical and functional presentations of geriatric asthma, including the partial loss of reversibility and the lower occurrence of the allergic component in this age range. The older asthmatic patients are also characterized the coexistence of comorbid …

Allergymedicine.medical_specialtyAgingAllergyImmunologyAlternative medicineDiseaseReviewSettore MED/10 - Malattie Dell'Apparato RespiratorioAging; Allergy; Asthma; TherapymedicineImmunology and AllergyIntensive care medicineMolecular BiologyNon pharmacologicalAsthma...COPDbusiness.industryAging; Allergy; Asthma; Therapy; Molecular Biology; Immunology and Allergy; ImmunologySettore MED/09 - MEDICINA INTERNAmedicine.diseaseTreatment efficacyAsthmarespiratory tract diseasesClinical trialImmunologyTherapybusiness
researchProduct

Pharmacological management of cancer pain in children

2014

The aim of this review was to assess cancer pain management in children on the basis of research published in the last ten years. Nine were papers providing clinical data, with a minimum of ten patients. No controlled studies were found. Regardless of general principles and existing recommendations, clinical data should confirm the applicability of this concept. The trials published in the last years did not provide further information to improve cancer pain management in children, because of the experience and the low number of drugs used, reflecting only meaningful opinions of experts in the field. The amount and the quality of data still remain poor, as only 737 subjects (about 80 patien…

Analgesicsmedicine.medical_specialtybusiness.industryCancer pain Pediatric painBreakthrough PainPharmacological managementAlternative medicinePainSettore MED/41 - AnestesiologiaHematologyPharmacologyClinical trialOncologyOpioidNeoplasmsHumansMedicineChildbusinessAdverse effectOpioid analgesicsIntensive care medicineCancer painmedicine.drug
researchProduct